Vitti Long Haul

Vitti Long Haul is dedicated to developing advanced therapies for individuals living with the lasting effects of COVID-19, with a focus on pulmonary fibrosis and long-haul symptoms. Our investigational treatments, VL-PX10 and VL-P22, are created using mesenchymal stem cells, exosomes, and biomaterials and are currently being studied in Phase 2 human clinical trials. For patients who may not qualify for trial participation, physician-guided access may be available through our Expanded Access Program. Supported by years of scientific research and developed in accordance with FDA guidelines, Vitti Long Haul remains committed to delivering innovative, safe, and effective treatment options. Patients and physicians are encouraged to contact us to learn more about enrollment and advanced care opportunities.